Company / Return on Equity (ROE)
ATOSSA THERAPEUTICS, INC. Return on Equity (ROE) History
FY2012-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-165.9%
FY2016
5-year range
-227.5% / -101.7%
FY2012-FY2016
Trend
-7.5%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
ATOSSA THERAPEUTICS, INC. reports negative total equity of -165.9% in FY2016. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-165.9% in FY2016 with a 3-year CAGR of +61.6%.
Declined from -101.7% to -165.9% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +61.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2016, return on equity (roe) decreased 7.5% year-over-year.
- Peak return on equity (roe) was recorded in FY2014.
- Lowest return on equity (roe) in the period was in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -15.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2016 | -165.9% | -7.5% |
| FY2015 | -154.3% | -51.7% |
| FY2014 | -101.7% | +55.3% |
| FY2013 | -227.5% | +0.0% |
| FY2012 | -227.5% | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026